Title: Genetic Disorder Cluster Muscular Dystrophy Drug Development Pipeline Market Review, 2017
1Genetic Disorder Cluster Muscular Dystrophy Drug
Development Pipeline Review, 2017
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
- Published May 2017
- Single User PDF US 3995
2Genetic Disorder Cluster Muscular Dystrophy Drug
Development Pipeline Review, 2017
- The Genetic Disorder Cluster Muscular Dystrophy
Drug Development Pipeline report provides an
overview of the genetic disorders pipeline
landscape. It provides information on the
therapeutics under development and key players
involved in therapeutic development for Becker
and Duchenne Muscular Dystrophy (BMD and DMD) and
features dormant and discontinued projects. Both
indications covered are inherited muscular
dystrophies, a group of genetic, degenerative
diseases primarily affecting voluntary muscles. - BMD, the first type of muscular dystrophy, leads
to symptoms include pain and sensation,
difficulty with running, hopping, and jumping,
toe walking, breathing problems, cognitive
problems and frequent falls. There are a total of
six products in development for this indication,
by six separate companies. - Access Complete Report at http//www.reportsnrepo
rts.com/reports/1001382-genetic-disorder-cluster-m
uscular-dystrophy-drug-development-pipeline-review
-2017.html. - Offers from 10th May 2017 to 2nd June 2017
- All reports priced gt1,000 20 Discount
Single User 25 Discount Global Site License. - Buy 2 Reports Get 1 Report Free
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
3Genetic Disorder Cluster Muscular Dystrophy Drug
Development Pipeline Review, 2017
- DMD is a condition which causes muscle weakness,
and is an X-linked disorder. The gene for DMD is
present on the X chromosome. It codes for a
protein named dystrophin. Dystrophin is essential
for providing structural support inside muscle
cells. - Symptoms usually appear before age 6 and may
appear as early as infancy. They include fatigue,
learning difficulties, intellectual disability,
muscle weakness and progressive difficulty
walking. - Key companies operating in this pipeline space
include Sarepta Therapeutics, PTC Therapeutics,
WAVE Life Sciences, Solid Biosciences, Summit
Therapeutics and Catabasis Pharmaceuticals. Of
particular importance are Sarepta, who are
developing twelve distinct pipeline products for
DMD. As with BMD, these are all smaller
enterprises, although there is some involvement
from larger pharmaceutical companies such as
Pfizer and Merck in the DMD pipeline. - There is a far larger pipeline for DMD than for
BMD there are a total of 108 products in
development for DMD, by 57 companies and nine
academic institutions. - Inquire for Discount http//www.reportsnreports.co
m/contacts/discount.aspx?name1001382.
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
4Genetic Disorder Cluster Muscular Dystrophy Drug
Development Pipeline Review, 2017
- Key Companies Operating in this Pipeline include
- The companies operating in this pipeline space
are all small pharmaceutical enterprises, and
consist of Armgo Pharma, Cardero Therapeutics,
Milo Biotechnology, PTC Therapeutics, ReveraGen
BioPharma and Sarepta Therapeutics. - The majority of pipeline products for DMD target
dystrophin which, as mentioned, is the causative
gene for the disease. However, a number of
products act on other molecular targets such as
growth differentiation factor 8, nuclear factor
kappa B and utrophin. The first two of these make
up the pipeline for BMD, along with fork head box
protein 1B. - Buy a Copy of Report _at_ http//www.reportsnreports.
com/purchase.aspx?name1001382.
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
5Genetic Disorder Cluster Muscular Dystrophy Drug
Development Pipeline Review, 2017
- Scope of the Report
- Which companies are the most active within the
pipeline for genetic disorder therapeutics? - Which pharmaceutical approaches are the most
prominent at each stage of the pipeline and
within each indication? - To what extent do universities and institutions
play a role within this pipeline, compared to
pharmaceutical companies? - What are the most important RD milestones and
data publications to have happened in the field
of genetic disorder therapeutics? - Buy a Copy of Report _at_ http//www.reportsnreports.
com/purchase.aspx?name1001382.
Order this report by calling 1 888 391 5441 or
Send an email to sales_at_reportsandreports.com with
your contact details and questions if any.
5
6About ReportsnReports
- ReportsnReports.com is your single source for all
market research needs. Our database includes
500,000 market research reports from over 95
leading global publishers in-depth market
research studies of over 5000 micro markets. - We provide 24/7 online and offline support to our
customers. - Contact
- Ritesh Tiwari
- Maharashtra, India.
- Tel 1-888-391-5441
- sales_at_reportsnreports.com